We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Illumina (ILMN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Illumina is a member of the Medical sector. This group includes 817 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ILMN is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ILMN's full-year earnings has moved 12.22% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ILMN has returned about 45.19% since the start of the calendar year. At the same time, Medical stocks have gained an average of 4.04%. As we can see, Illumina is performing better than its sector in the calendar year.
To break things down more, ILMN belongs to the Medical - Biomedical and Genetics industry, a group that includes 327 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, this group has lost an average of 12.66% so far this year, meaning that ILMN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to ILMN as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Illumina (ILMN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Illumina is a member of the Medical sector. This group includes 817 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ILMN is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ILMN's full-year earnings has moved 12.22% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ILMN has returned about 45.19% since the start of the calendar year. At the same time, Medical stocks have gained an average of 4.04%. As we can see, Illumina is performing better than its sector in the calendar year.
To break things down more, ILMN belongs to the Medical - Biomedical and Genetics industry, a group that includes 327 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, this group has lost an average of 12.66% so far this year, meaning that ILMN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to ILMN as it looks to continue its solid performance.